Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 18.23M P/E - EPS this Y 7.10% Ern Qtrly Grth -
Income -53.05M Forward P/E -0.58 EPS next Y 60.10% 50D Avg Chg 2.00%
Sales 8.24M PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 0.29 EPS next 5Y - 52W High Chg -80.00%
Recommedations 3.00 Quick Ratio 0.28 Shares Outstanding 36.03M 52W Low Chg 40.00%
Insider Own 7.33% ROA -36.10% Shares Float 24.16M Beta 0.18
Inst Own 8.61% ROE -93.63% Shares Shorted/Prior 306.62K/201.22K Price 0.70
Gross Margin - Profit Margin - Avg. Volume 143,429 Target Price -
Oper. Margin -1,529.44% Earnings Date Mar 29 Volume 39,423 Change -2.10%
About NightHawk Biosciences, Inc.

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.